Article Details

Lyndra banks $60.5M to bring ultralong-acting pill into pivotal schizophrenia trial

Retrieved on: 2021-06-24 12:00:00

Tags for this article:

Click the tags to see associated articles and topics

Lyndra banks $60.5M to bring ultralong-acting pill into pivotal schizophrenia trial. View article details on hiswai:

Excerpt

... which led the funding round, alongside the likes of Gilead Sciences, Polaris Partners, Mass General Brigham Ventures and HOPU Investments.

Article found on: www.fiercebiotech.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up